Advertisement
Advertisement
PTHS
Pelthos Therapeutics Inc.
28.36
USDSponsored
-1.09
-3.70%
Aug 07, 15:59 UTC -4
Closed
Pre-Market
28.36
0.00
0.00%
PTHS Earnings Reports
Positive Surprise Ratio
PTHS beat 3 of 7 last estimates.
43%
Next Report
In 3 Days
Date of Next Report
Aug 13, 2026
Estimate for Q2 26 (Revenue/ EPS)
$15.58M
/-$3.10
Implied change from Q1 26 (Revenue/ EPS)
+42.84%
/+0.32%
Implied change from Q2 25 (Revenue/ EPS)
--
/-42.38%
Pelthos Therapeutics Inc. earnings per share and revenue
On May 14, 2026, PTHS reported earnings of -3.09 USD per share (EPS) for Q1 26, beating the estimate of -3.34 USD, resulting in a 7.55% surprise. Revenue reached 10.91 million, compared to an expected 10.65 million, with a 2.36% difference. The market reacted with a +6.46% price change (close before vs. close after earnings).
Looking ahead to Q2 26, -- analysts forecast an EPS of -3.10 USD, with revenue projected to reach 15.58 million USD, implying an increase of 0.32% EPS, and increase of 42.84% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
REGENXBIO Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.05
Actual
$0.43
Surprise
+626.35%
X4 Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
SAB Biotherapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.29
Actual
-$0.28
Surprise
+5.15%
Cellectis S.A. - ADR
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.22
Surprise
+20.89%
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
Genmab A/S ADS
Report Date
Aug 06, 2026 For Q2 26
Estimate
$3.59
Actual
$0.54
Surprise
-84.98%
Praxis Precision Medicines, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$3.73
Actual
-$2.87
Surprise
+23.14%
Halozyme Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
$1.87
Actual
$2.27
Surprise
+21.75%
Cytokinetics Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.67
Actual
-$1.50
Surprise
+10.35%
FAQ
What were Pelthos Therapeutics Inc.'s earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Pelthos Therapeutics Inc. reported EPS of -$3.09, beating estimates by 7.55%, and revenue of $10.91M, 2.36% above expectations.
How did the market react to Pelthos Therapeutics Inc.'s Q1 2026 earnings?
The stock price moved up 6.46%, changed from $26.01 before the earnings release to $27.69 the day after.
When is Pelthos Therapeutics Inc. expected to report next?
The next earning report is scheduled for Aug 13, 2026.
What are the forecasts for Pelthos Therapeutics Inc.'s next earnings report?
Based on --
analysts, Pelthos Therapeutics Inc. is expected to report EPS of -$3.10 and revenue of $15.58M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement